{
  "ticker": "RAPP",
  "company_name": "Rapport Therapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT07046494",
      "title": "Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Bipolar 1 Disorder",
      "start_date": "2025-07-25",
      "completion_date": "2026-12",
      "enrollment": 0,
      "sponsor": "Rapport Therapeutics Inc."
    },
    {
      "nct_id": "NCT06377930",
      "title": "Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Focal Onset Seizures",
      "start_date": "2024-10-10",
      "completion_date": "2025-09-22",
      "enrollment": 0,
      "sponsor": "Rapport Therapeutics Inc."
    },
    {
      "nct_id": "NCT07219407",
      "title": "A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure, Focal Seizure, Focal Onset Seizure",
      "start_date": "2025-12-15",
      "completion_date": "2028-02-03",
      "enrollment": 0,
      "sponsor": "Rapport Therapeutics Inc."
    }
  ],
  "summary": {
    "total_trials": 3,
    "by_phase": {
      "PHASE2": 3
    },
    "by_status": {
      "RECRUITING": 2,
      "ACTIVE_NOT_RECRUITING": 1
    },
    "active_trials": 3,
    "completed_trials": 0,
    "conditions": [
      "Bipolar 1 Disorder",
      "Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure, Focal Seizure, Focal Onset Seizure",
      "Focal Onset Seizures"
    ],
    "lead_stage": "phase_2"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:21:18.744025",
    "search_query": "Rapport Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Rapport+Therapeutics,+Inc."
  }
}